Showing 471-480 of 10585 results for "".
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
https://reachmd.com/programs/cme/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/54306/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Advances in Managing Neuropsychiatric Symptoms of Alzheimer’s Disease: From Early Detection to Emerging Therapies
https://reachmd.com/programs/cme/advances-in-managing-neuropsychiatric-symptoms-of-alzheimers-disease-from-early-detection-to-emerging-therapies/35729/Learn about the diagnosis of NPS associated with Alzheimer’s disease and explore current and emerging treatment options.Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
https://reachmd.com/programs/cme/future-proofing-in-hae-advances-in-long-term-prophylaxis-to-prevent-attacks-and-improve-quality-of-life/54448/On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): Overcoming Diagnostic and Therapeutic Challenges
https://reachmd.com/programs/cme/fetal-and-neonatal-alloimmune-thrombocytopenia-fnait-overcoming-diagnostic-and-therapeutic-challenges/29105/FNAIT is the platelet equivalent of Rh disease. Managing this alloimmune disorder of pregnancy poses many challenges for clinicians. Learn more here!Current & Emerging Therapies: Treating & Preventing Hereditary Angioedema Attacks in Children & Adults
https://reachmd.com/programs/cme/current-emerging-therapies-treating-preventing-hereditary-angioedema-attacks-in-children-adults/37604/Provided by RMEI Medical Education, LLC. Supported by independent educational grants from Intellia Therapeutics, Pharming Healthcare, Inc., and Pharvaris.Beyond Cognition: Managing Alzheimer’s as an Integrated Neurodegenerative–Neuropsychiatric Syndrome
https://reachmd.com/programs/cme/Beyond-Cognition-Managing-Alzheimers-as-an-Integrated-Neurodegenerative-Neuropsychiatric-Syndrome/54842/Examine integrated neurodegenerative and neuropsychiatric features of Alzheimer’s disease, including NPS biology and therapeutic strategies.MIRASOL Insights in PROC: A Biomarker-Driven Approach
https://reachmd.com/programs/project-oncology/mirasol-proc-biomarker-approach/37252/In platinum-resistant ovarian cancer (PROC), survival is usually measured in months,1-3 and most patients will have already received multiple prior lines of therapy.4 Biomarker-driven therapy has helped change the treatment landscape.5-10 Tune in to learn more about mirvetuximab soravtansine-gynx asDetangling Difficult Conversations About Multiple Sclerosis: Clinical Exchanges
https://reachmd.com/programs/cme/detangling-difficult-conversations-about-multiple-sclerosis-clinical-exchanges/10627/This conversation-centered activity with educational pearls takes learners through a clinical exchange between patients with MS and their providers.HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
https://reachmd.com/programs/cme/her2-in-bladder-cancer-breaking-through-the-molecular-frontier/35561/Explore HER2 as a therapeutic target in bladder cancer, from molecular testing to HER2-directed treatment strategies and multidisciplinary AE management.Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
https://reachmd.com/programs/project-oncology/radium-223s-potential-quality-of-life-benefits-for-mcrpc-patients/28642/Dive into a study that explored how radium-223 may be able to boost the quality of life of patients battling metastatic castration-resistant prostate cancer.